Clinical and Economic Outcomes Associated with Urinary Tract Infections Caused by Extended Spectrum Beta-lactamase Producing Bacteria in a Tertiary Care Hospital

Sözen, Hamdi; Çaylak, Selmin Dirgen; Çetinkaya, Mehmet; Çitil, Burak Ekrem; Şahin, Cem; Deliktaş, Hasan; Aksozek, Alper; Kırlı, İsmail

doi:10.1080/09735070.2015.11905432

Cited by 4 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Still, it was reported that resistance to CIP in E. coli from UTI in Denmark was increasing parallel to increased use of fl uoroquinolones, which also shown for another European countries [24]. Resistance to CIP, which are the preferred empiric treatment for UTI, prolongs hospitalization and increases the cost of antibiotic treatment [25].…”

Section: Discussionmentioning

confidence: 99%

The analysis of antibiotic consumption and bacterial resistance in tertiary Healthcare Centre Nis

Velickovic-Radovanovic¹,

Stefanović²,

Damnjanovic³

et al. 2016

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The analysis of antibiotic consumption and bacterial resistance in tertiary Healthcare Centre Nis

Velickovic-Radovanovic¹,

Stefanović²,

Damnjanovic³

et al. 2016

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

“…[ 2 , 22 , 23 , 25 ] This is likely from the fact that the plasmid carrying the ESBL gene can acquire other resistance genes that may confer resistance to other antibiotic classes, especially in hospital setup. [ 8 , 24 , 25 , 26 , 27 ] Other researchers have reported similar findings, where ESBL production was more frequent in E. coli followed by K. pneumoniae . [ 22 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ] A study reported a very high prevalence of ESBL of 84% in E. coli among patients with UTI in India.…”

Section: Discussionmentioning

confidence: 66%

“…reported a relatively low value of 26.6% in Sudan. [ 27 ] The findings of a relatively high prevalence of ESBL in this study are most likely due to the use and misuse of antibiotics, especially the third-generation cephalosporins which are workhorses for most physicians in our health-care facilities. The differences in ESBL prevalence reported can be explained by the methodologies used in the different studies as well as the geographical peculiarities of the various regions.…”

Section: Discussionmentioning

confidence: 89%

Antimicrobial Susceptibility Pattern of Extended-Spectrum Beta-Lactamase-Producing Uropathogens in Aminu Kano Teaching Hospital, Northwestern Nigeria

Umar,

Giwa,

Ibrahim

et al. 2023

Annals of African Medicine

View full text Add to dashboard Cite

Background: UTI is the most common nosocomial infection among hospitalized patients. Emerging increasing resistance has been observed among uropathogens of the family enterobacterales. Extended spectrum beta lactamase genes encode for multidrug resistance and unrestricted use of antibiotics in hospitals provides an environment for spread of infections with limited treatment options. This necessitates therapies based on culture and antimicrobial sensitivity to improve patients’ outcomes We aimed to determine susceptibility pattern of ESBL uropathogens among hospitalized patients in Aminu Kano Teaching Hospital, Kano. Methodology: Three hundred and eighty-nine urine samples were obtained from in-patients with UTI between April 2020 and April 2021. Five samples were rejected and remaining analyzed. Susceptibility testing was done by modified Kirby Bauer technique. Clinical Laboratory Standards Institute guidelines 2019 (CLSI 2019) and the European Committee on Antimicrobial Susceptibility testing guidelines version 2 (EUCAST version 2) were used for screening and confirmation of ESBL production respectively. Results: Of the 384-urine processed, 105 (27.3%) were gram negatives and 81 were Enterobacterales, Isolation rates were E. coli-55.6%, K. pneumoniae-29.6%, Citrobacter spp.-12.3%, P. mirabilis-1.2% and Morganella spp.-1.2%. Among Enterobacterales, 32 (39.5%) were ESBL producers. Prevalence of ESBL were 62.5% for Escherichia coli, 28.1% for Klebsiella pneumoniae and 9.4% for Citrobacter species. Susceptibility showed that ESBL-producing Isolates were highly susceptible to amikacin (96.9%). Resistance to other antibiotics varied from 3.1% to 100%. Conclusion: We recommend strengthening laboratory capacity, antibiotics stewardship and Infection control to prevent spread of resistant pathogens including ESBLs.

show abstract

Estimating the burden of antimicrobial resistance: a systematic literature review

Naylor

Atun

Zhu

et al. 2018

Antimicrob Resist Infect Control

381

314

View full text Add to dashboard Cite

BackgroundAccurate estimates of the burden of antimicrobial resistance (AMR) are needed to establish the magnitude of this global threat in terms of both health and cost, and to paramaterise cost-effectiveness evaluations of interventions aiming to tackle the problem. This review aimed to establish the alternative methodologies used in estimating AMR burden in order to appraise the current evidence base.MethodsMEDLINE, EMBASE, Scopus, EconLit, PubMed and grey literature were searched. English language studies evaluating the impact of AMR (from any microbe) on patient, payer/provider and economic burden published between January 2013 and December 2015 were included. Independent screening of title/abstracts followed by full texts was performed using pre-specified criteria. A study quality score (from zero to one) was derived using Newcastle-Ottawa and Philips checklists. Extracted study data were used to compare study method and resulting burden estimate, according to perspective. Monetary costs were converted into 2013 USD.ResultsOut of 5187 unique retrievals, 214 studies were included. One hundred eighty-seven studies estimated patient health, 75 studies estimated payer/provider and 11 studies estimated economic burden. 64% of included studies were single centre. The majority of studies estimating patient or provider/payer burden used regression techniques. 48% of studies estimating mortality burden found a significant impact from resistance, excess healthcare system costs ranged from non-significance to $1 billion per year, whilst economic burden ranged from $21,832 per case to over $3 trillion in GDP loss. Median quality scores (interquartile range) for patient, payer/provider and economic burden studies were 0.67 (0.56-0.67), 0.56 (0.46-0.67) and 0.53 (0.44-0.60) respectively.ConclusionsThis study highlights what methodological assumptions and biases can occur dependent on chosen outcome and perspective. Currently, there is considerable variability in burden estimates, which can lead in-turn to inaccurate intervention evaluations and poor policy/investment decisions. Future research should utilise the recommendations presented in this review.Trial registrationThis systematic review is registered with PROSPERO (PROSPERO CRD42016037510).Electronic supplementary materialThe online version of this article (10.1186/s13756-018-0336-y) contains supplementary material, which is available to authorized users.

show abstract

Clinical and Economic Outcomes Associated with Urinary Tract Infections Caused by Extended Spectrum Beta-lactamase Producing Bacteria in a Tertiary Care Hospital

Cited by 4 publications

References 1 publication

The analysis of antibiotic consumption and bacterial resistance in tertiary Healthcare Centre Nis

The analysis of antibiotic consumption and bacterial resistance in tertiary Healthcare Centre Nis

Antimicrobial Susceptibility Pattern of Extended-Spectrum Beta-Lactamase-Producing Uropathogens in Aminu Kano Teaching Hospital, Northwestern Nigeria

Estimating the burden of antimicrobial resistance: a systematic literature review

Contact Info

Product

Resources

About